SAN DIEGO, CA, Dec. 4 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation announced today that Margot Northey, Ph.D., is leaving the Board of Directors effective as of today to pursue other interests.
Jay M. Short, Ph.D., Chairman of Nventa’s Board of Directors, commented on the Board change: “As the former Dean of the School of Business at Queen’s University, Margot’s knowledge, combined with her experience from other Board positions, was a tremendous asset to the Nventa Board. We will miss her and wish her continued success in all of her future endeavors.”
“We are very appreciative of Margot’s contribution to the Board,” said Gregory M. McKee, Nventa’s President and Chief Executive Officer. “With the Board’s support, we have advanced the development of HspE7, our investigational therapeutic vaccine for human papillomavirus (HPV)-related diseases, into a Phase 1 clinical trial in women with cervical dysplasia.”
About Nventa Biopharmaceuticals Corporation:
Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The Company is publicly traded on the Toronto Stock Exchange under the symbol NVN. For more information about Nventa Biopharmaceuticals Corporation, please visit the Company’s website located at www.nventacorp.com.
CONTACT: Donna Slade, Director, Investor Relations, 9381 Judicial Drive, Suite 180, San Diego, CA, USA, 92121, Direct: (858) 202-4945, dslade@nventacorp.com
CONTACT: Donna Slade, Director, Investor Relations, 9381 Judicial Drive,
Suite 180, San Diego, CA, USA, 92121, Direct: (858) 202-4945,
dslade@nventacorp.com
